Atomoxetine (Strattera) for ADHD: risk of psychotic or manic symptoms
The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2009. One of the drugs reviewed is atomoxetin (Strattera), a norepinephrine reuptake inhibitor used for the treatment of ADHD. These are the recommendations: Advice for healthcare professionals: • At normal doses, atomoxetine can be associated with treatment-emergent psychotic or manic […]
EMEA reviewed methylphenidate (Ritalin) for ADHD and issued recommendations for its safer use
EMEA’s Committee for Medicinal Products for Human Use (CHMP) has reviewed methylphenidate for attention deficit/hyperactivity disorder (ADHD). Quoting the press release issued 22 January 2009: The European Medicines Agency (EMEA) has concluded that methylphenidate-containing medicines remain suitable for the treatment of children aged six years or older and adolescents with attention deficit/hyperactivity disorder (ADHD). It has […]
Atomoxetine (Strattera) and the risk of serious hepatic damage. FDA recommendations
From the FDA Drug Safety Newsletter Vol. 2 Number 1, 2009: Atomoxetine (Marketed as Strattera): Serious Liver Injury Abstract: In 2004, the atomoxetine label was updated to include information about cases of serious liver injury. From January 2005 to March 2008, six postmarket cases of serious liver injury with atomoxetine use were reported to FDA. […]